Pulse Biosciences Files 510(k) Submission With US FDA For Its CellFX nsPFA Percutaneous Electrode
Portfolio Pulse from Benzinga Newsdesk
Pulse Biosciences has submitted a 510(k) application to the US FDA for its CellFX nsPFA Percutaneous Electrode, a device that could potentially enhance the company's product offerings in the medical device market.
November 21, 2023 | 1:04 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Pulse Biosciences' 510(k) submission for the CellFX nsPFA Percutaneous Electrode to the FDA could lead to an expansion of its product line and potentially increase its market share in the medical device sector.
The submission of a 510(k) application is a critical regulatory step for medical devices. If approved, Pulse Biosciences' CellFX nsPFA Percutaneous Electrode could see increased adoption and sales, positively impacting the company's revenue and market position. The confidence score is not at the maximum because the FDA's decision is pending, and the outcome is uncertain.
CONFIDENCE 75
IMPORTANCE 80
RELEVANCE 100